GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celltrion Inc (XKRX:068270) » Definitions » Total Liabilities

Celltrion (XKRX:068270) Total Liabilities : ₩2,791,740 Mil (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Celltrion Total Liabilities?

Celltrion's Total Liabilities for the quarter that ended in Dec. 2023 was ₩2,791,740 Mil.

Celltrion's quarterly Total Liabilities increased from Jun. 2023 (₩1,895,104.20 Mil) to Sep. 2023 (₩2,075,037.90 Mil) and increased from Sep. 2023 (₩2,075,037.90 Mil) to Dec. 2023 (₩2,791,739.99 Mil).

Celltrion's annual Total Liabilities declined from Dec. 2021 (₩1,623,747.85 Mil) to Dec. 2022 (₩1,617,448.04 Mil) but then increased from Dec. 2022 (₩1,617,448.04 Mil) to Dec. 2023 (₩2,791,739.99 Mil).


Celltrion Total Liabilities Historical Data

The historical data trend for Celltrion's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celltrion Total Liabilities Chart

Celltrion Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 986,733.42 1,592,540.90 1,623,747.85 1,617,448.04 2,791,739.99

Celltrion Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,617,448.04 1,848,149.15 1,895,104.20 2,075,037.90 2,791,739.99

Celltrion Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Celltrion's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2470579.211+(107115.929+214044.85
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=2,791,740

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=19917534.297-17125794.307
=2,791,740

Celltrion's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2470579.211+(107115.929+214044.85
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=2,791,740

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=19917534.297-17125794.307
=2,791,740

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celltrion Total Liabilities Related Terms

Thank you for viewing the detailed overview of Celltrion's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Celltrion (XKRX:068270) Business Description

Traded in Other Exchanges
N/A
Address
13-6 SongDo-Dong, Yeonsu-gu, Incheon City, KOR, 406-840
Celltrion Inc is a Korea-based company principally engaged in the research, development, and manufacture of therapeutic proteins. The company mainly manufactures biosimilar products, which are used to treat breast cancer, rheumatoid arthritis disease, Crohn's disease, Hodgkin's lymphoma, colorectal cancer, rheumatoid arthritis, respiratory syncytial virus, colon cancer, and others.

Celltrion (XKRX:068270) Headlines

No Headlines